Late preterm infants (34-36 weeks' gestation) are more susceptible to infection by respiratory syncytial virus (RSV) because of the immaturity of both the respiratory and the immune system. Prevention of RSV infections is based on environmental avoidance and passive immunoprophylaxis with palivizumab, a specific anti-RSV humanized monoclonal antibody, proven to be effective in reducing the overall hospitalization rate for RSV-induced bronchiolitis in preterm newborns. The American Academy of Pediatrics has been recently updated the prophylaxis guidelines for newborns 33-35 weeks' gestation. Nevertheless some considerations are due for application of those new guidelines in our countries.
|Translated title of the contribution||Prevention of respiratory syncytial virus infections in late preterm newborns|
|Number of pages||6|
|Publication status||Published - Feb 2011|
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health